Patents
Retro-inverso peptides derived from interleukin-3
Patent Number: 7,115,571IL-3 is a potent expander of hematopoietic stem cells. Unfortunately administration of proteins is associated with poor pharmacokinetics and the need to develop special formulations that can systemically deliver the protein. This patent covers peptide derivatives of IL-3 which have improved activity and pharmacological activity compared to administration of the whole protein. This patent is...
Inventors: Wright; David E. (Ramona, CA), Parks; D. Elliott (Del Mar, CA)
Assignee: Myelos Corporation (Iselin, NJ)
Date of First Priority Issue: Friday June 16th, 2000
Methods of proliferating undifferentiated neural cells
Patent Number: 7,115,418This patent teaches ways of expanding neural stem cells without inducing loss of replicative ability. Specifically, this involves culture with one or more growth factors selected from a group comprising of EGF, amphiregulin, FGF-1, FGF-2 and TGF-beta.
Inventors: Weiss; Samuel (Alberta, CA), Reynolds; Brent (Alberta, CA), Hammang; Joseph P. (Barrington, RI), Baetge; E. Edward (Barrington, RI)
Assignee: Neurospheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
Patent Number:This patent covers the extraction and use of a muscle derived stem cell that is positive for the markers desmin, CD34, flk-1 and M-Cadherin, but does not express the hematopoietic marker CD45 nor c-kit. This cell type is useful for treatment of a variety of disorders associated with muscle degeneration. Although the inventors state that the cell is different than mesenchymal stem cells, in...
Inventors: Chancellor; Michael B. (Pittsburg, PA), Huard; Johnny (Pittsburgh, PA), Capelli; Christopher C. (Kenosha, WI), Qu; Zhuqing (Pittsburgh, PA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday May 1st, 1998
Isolation and use of solid tumor stem cells
Patent Number: 7,115,360The cancer stem cell is very important since there is numerous investigators in the field that believe the majority of cancer cells making up a tumor mass are only the products of a specific cell subpopulation with high repopulating potential. What this means is that usually the drugs developed for cancer are developed to kill not the stem cell of the tumor, but actually the progeny of the...
Inventors: Clarke; Michael F. (Ann Arbor, MI), Morrison; Sean J. (Ann Arbor, MI), Wicha; Max S. (Ann Arbor, MI), al-Hajj; Muhammad (La Jolla, CA)
Assignee: Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday August 3rd, 2000
Stimulator of stem cell division
Patent Number: 7,115,267This patent covers various hemaglobin beta chain derived sequences of peptides, as well as their use in combination with opioids for augmentation of hematopoiesis, as well as for antiviral and anticancer activities. The products claimed by the patent appear easy to generate and are potentially useful for other regenerative applications besides stimulation of hematopoiesis.
Inventors: Wolpe; Stephen D. (Rockville, MD), Tsyrlova; Irena (Gaithersburg, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday April 3rd, 1996
Methods of culturing embryonic stem cells and controlled differentiation
Patent Number: 7,112,437This patent covers ways of generating human neural stem cells, or committed stem cells, from embryonic stem cells. The patent has 2 independent claims. The first teaches culturing of the embryonic stem cells with an agent that inhibits a bone morphogenic protein "default pathway" so that the differentiated cell that is produced loses at least one marker of the embryonic stem cell. This...
Inventors: Pera; Martin Frederick (Prahran, AU)
Assignee: ES Cell International Pte Ltd. (Singapore, SG)
Date of First Priority Issue: Tuesday June 20th, 2000
Retro-inverso peptides derived from leukemia inhibitory factor
Patent Number: 7,109,168Leukemia inhibitory factor (LIF) is classically known for its ability to maintain murine embryonic stem cells in an undifferentiated state. Various types of non-embryonic stem cells also respond to LIF. For example, LIF supplementation to human fetal cortical cells increases telomerase activity and endows increased self-renewal potential (Wright et al. Human progenitor cells isolated from the...
Inventors: Wright; David E. (Ramona, CA), Parks; D. Elliott (Del Mar, CA)
Assignee: Myelos Corporation (Iselin, NJ)
Date of First Priority Issue: Sunday July 16th, 2000
Serum-free medium for mesenchymal stem cells
Patent Number: 7,109,032This patent covers a tissue culture media composition that dose not require the addition of exogenous sera. The tissue culture composition is suitable for expanding mesenchymal stem cells and alleviates the need for serum through addition of the following proteins which are known to stimulate various types of stem cells: basic fibroblast growth factor, leukemia inhibitory factor, and stem cell...
Inventors: Cancedda; Ranieri (Genoa, IT), Dozin; Beatrice (Rapallo, IT)
Assignee: Consorzio per la Gestione del Centro di Biotecnologie Avanzate (Genoa, IT)
Date of First Priority Issue: Monday November 9th, 1998
Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
Patent Number: 7,109,030This is a composition of matter patent on polypeptides homologous to insulin like growth factor binding protein (IGFBP). Various members of the IGFBP family, such as IGFBP-3, stimulate hematopoietic cell proliferation (Liu et al. Functional cloning of IGFBP-3 from human microvascular endothelial cells reveals its novel role in promoting proliferation of primitive CD34+CD38- hematopoietic cells in...
Inventors: Dedera; Douglas A. (Castro Valley, CA), Yamazaki; Victoria (Redwood Shores, CA), Asundi; Vinod (Foster City, CA), Liu; Chenghua (San Jose, CA), Tang; Y. Tom (San Jose, CA), Drmanac; Radoje T. (Palo Alto, CA)
Assignee: Nuvelo, Inc. (San Carlos, CA)
Date of First Priority Issue: Friday March 31st, 2000
Myocardial grafts and cellular compositions
Patent Number: RE37,978This patent is useful for anyone who is performing embryonic stem cell differentiation applications and desires a method of purifying unique differentiated cells from the embryonic stem cell. Since embryonic stem cells spontaneously differentiate into various lineages depending on culture conditions, this patent provides means of "fishing out" cells based on activation of cell-specific...
Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Advanced Research & Technology Institute (Indianapolis, IN)
Date of First Priority Issue: Tuesday November 16th, 1993